Vega Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
South San Francisco, CA
Type:
sample
Technology:
sample
sample
About: Vega Therapeutics is a clinical stage biotechnology company developing novel, first-in-class therapies for rare blood disorders with overlooked patient needs, starting with von Willebrand disease (VWD). Our lead product candidate, VGA039, is the first purpose-built antibody therapy for VWD with a novel mechanism of action targeting Protein S. By attenuating Protein S cofactor function for tissue factor pathway inhibitor α (TFPIα) and activated protein C (aPC), VGA039 augments and restores thrombin generation during both initiation and propagation of coagulation, addressing a fundamental mechanism of clot formation in VWD. VGA039 has potential to be a universal hemostatic therapy that can treat various bleeding disorders. Vega is part of a constellation of companies led by Star Therapeutics, a company focused on developing life-changing therapies for people with rare diseases.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Vega Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.